As a wholly-owned subsidiary of Huawei Pharmaceutical Group Co., Ltd., Beijing Huawei Medical LLC is responsible for the sales and market of medical products. With a hard-working sales team of outstanding expertise and marketing experience, the Company has expanded its market to more than 30 provinces and cities, including over 500 tertiary hospitals and over 1,000 communities and secondary hospitals and promoted its products of pediatrics, pneumology, oncology, hematology, gynecology, orthopedics, hepatology and gastroenterology internal medicine with an annual turnover of exceeding RMB 500 million. Meanwhile, the Company has established long-term strategic partnerships with plenty of pharmaceutical companies. Its operation philosophy is “win-win cooperation”, “providing excellent service” and “serving as a good partner”.
Huawei Pharmaceutical Development and Consulting (Beijing) Co., Ltd. is a wholly-owned subsidiary of Huawei Pharmaceutical Group Co., Ltd. Targeting at medical programs failing to meet patients' demands and with the Medical Excellence Japan (MEJ) as a strategic partner, the company is developing world-leading medical products and introducing globally advanced medical programs for the benefit of people's health, based on cooperation in medical products developed by Japan. Now, we have introduced Cefcapene Pivoxil Hydrochloride Granules from Japan’s Shionogi Inc.
Since 2017, we have carried out multiple exchanges and cooperation with PMDA, MEJ, Japanese Medical Association, etc.(1).jpg)
We cooperate with Japanese pharmaceutical and medical device companies to develop businesses and establish projects of pharmaceutical products introduced.
In addition to self-developed products, we serve as an agent for pharmaceutical products of domestic and foreign companies, develop products and register them for marketing.
We implement clinical research of pharmaceutical products to support domestic and foreign pharmaceutical companies.
We help domestic and foreign pharmaceutical companies connect with the pharmaceutical regulatory authority and implement policy consulting activities on product development, registration and so on.
We assist pharmaceutical companies in China and Japan to conduct investment, cooperation and joint research and development of new products in the frontier of pharmaceutical innovation.
ADD：2812/2815/2816/2817, Nanyin building, No. 2, East Third Ring North Road, Chaoyang District, Beijing
Tel：+86-10-61006202/61006203
Fax：+86-10-61006309
URL：www.moh-hw.com
Copyright(C)2022,Huawei Pharmaceutical Group All Rights Reserved.
Supported by Toocle 31fabu Copyright Notice
